10-Q: Avanos Medical Reports Q2 Loss Amid $77M Goodwill Impairment

Avanos Medical, Inc. reported a significant net loss for the second quarter of 2025, primarily driven by a $77.0 million goodwill impairment charge related to its Pain Management and Recovery segment, despite modest revenue growth.

Summary

• Net sales increased 1.9% to $175.0 million for the three months ended June 30, 2025, and 1.4% to $342.5 million for the six months ended June 30, 2025, compared to the prior year periods.
• A net loss of $76.8 million was reported for Q2 2025, a significant decline from a net income of $1.8 million in Q2 2024, primarily due to a $77.0 million goodwill impairment charge.
• For the first six months of 2025, a net loss of $70.2 million was reported, compared to a net income of $0.9 million in H1 2024.
• Specialty Nutrition Systems (SNS) net sales grew 5.1% in Q2 2025 to $102.7 million and 6.0% in H1 2025 to $203.8 million, driven by strong demand in enteral feeding and neonate solutions.
• Pain Management and Recovery (PM&R) net sales increased 2.9% in Q2 2025 to $61.0 million and 1.4% in H1 2025 to $117.2 million, with strong Radiofrequency Ablation (RFA) growth (13.7% in Q2, 11.0% in H1) partially offset by a decline in surgical pain and recovery products (9.4% in Q2, 9.3% in H1).
• Cash and cash equivalents decreased by $17.4 million to $90.3 million as of June 30, 2025, from $107.7 million at December 31, 2024.
• Cash provided by operating activities increased to $32.5 million for the six months ended June 30, 2025, up from $19.8 million in the prior year period.
• The company sold substantially all assets related to its Hyaluronic Acid (HA) product line on July 31, 2025, aligning with its strategic focus on PM&R and SNS.

Sentiment

Score: 3

Explanation: The significant goodwill impairment charge and resulting net loss overshadow modest revenue growth and positive operational cash flow. While strategic divestitures and restructuring are underway, the immediate financial impact is negative, indicating underlying challenges in asset valuation and profitability for a key segment.

Positives

• Specialty Nutrition Systems (SNS) segment demonstrated strong demand and growth, with net sales increasing 5.1% in Q2 2025 and 6.0% in H1 2025.
• Radiofrequency Ablation (RFA) solutions within the Pain Management and Recovery (PM&R) segment showed robust growth of 13.7% in Q2 2025 and 11.0% in H1 2025, driven by increased generator sales and procedures.
• Cash provided by operating activities significantly increased to $32.5 million for the six months ended June 30, 2025, compared to $19.8 million in the prior year period.
• Interest expense decreased to $2.0 million in Q2 2025 and $4.1 million in H1 2025, from $3.1 million and $6.2 million respectively in the prior year periods.
• The company successfully completed the transfer of manufacturing facilities and equipment related to the RH Divestiture on October 1, 2024, and the DOJ case related to MicroCool surgical gowns was dismissed in January 2025.
• Selling and general expenses decreased for the six months ended June 30, 2025, driven by savings realized from the execution of the Transformation Process and increased spending discipline.

Negatives

• A significant goodwill impairment charge of $77.0 million was recorded in Q2 2025, primarily impacting the Pain Management and Recovery (PM&R) reporting unit.
• A net loss of $76.8 million was reported for Q2 2025 and $70.2 million for H1 2025, a substantial decline from net income in the prior year periods.
• Operating income shifted to a loss of $74.5 million in Q2 2025 and $64.2 million in H1 2025, compared to income in the prior year periods, primarily due to the goodwill impairment.
• Surgical pain and recovery net sales within the PM&R segment decreased by 9.4% in Q2 2025 and 9.3% in H1 2025 due to lower volume.
• Gross profit decreased to $92.1 million in Q2 2025 from $95.6 million in Q2 2024, and to $181.9 million in H1 2025 from $190.4 million in H1 2024.
• Cash and cash equivalents decreased by $17.4 million to $90.3 million as of June 30, 2025.
• Increased costs of products sold due to higher tariffs along with increases in net sales across both reportable segments.
• Incurred $2.0 million and $3.7 million of expense for inventory write-offs and obsolescence in the three and six months ended June 30, 2025, respectively.

Risks

• General economic conditions, particularly in the United States, could adversely affect the level of demand for products.
• Pricing pressures generally, including cost-containment measures, could adversely affect the price of or demand for products.
• Fluctuations in global equity and fixed-income markets.
• Ability to successfully execute on or achieve the expected benefits of restructuring initiatives.
• Supply chain issues and inflationary pressures.
• A resurgence of the COVID-19 pandemic.
• Changes in the competitive environment.
• Loss of current customers or the inability to obtain new customers.
• Cybersecurity threats, including breaches of or cyberattacks on information systems.
• Ongoing regional conflicts between Russia and Ukraine and in the Middle East.
• Concentration of manufacturing operations in Mexico.
• Financial conditions affecting the banking system and the potential threats to the solvency of commercial banks.
• Litigation and enforcement actions.
• Disruption in the supply of raw materials or the distribution of finished goods.
• Price fluctuations in key commodities.
• The expected impact of tariffs and ability to mitigate tariffs.
• New or increased tariffs.
• Changes in, or revised interpretations of, import-export laws or international trade agreements.
• Fluctuations in currency exchange rates.
• Changes in governmental regulations that are applicable to the business.
• Ability to realize the intended benefits of restructuring initiatives or divestiture, acquisition, or merger transactions.
• Changes in asset valuations, including write-downs of assets such as inventory, accounts receivable, or other assets for impairment or other reasons.
• The recent imposition of new tariffs by the United States, along with retaliatory tariffs and other trade restrictions imposed by other countries, could have a material adverse effect on business, financial condition, results of operations, and cash flows.
• The U.S. administration's antipathy towards certain existing international trade agreements and organizations (e.g., USMCA, WTO) could result in additional increased tariffs or other new trade restrictions on imports from Mexico, Canada, China, and other countries.
• Retaliatory tariffs from other countries could increase the cost of products in those countries, negatively impacting customer demand and revenues.

Future Outlook

Operating cash flow is expected to be sufficient to meet working capital requirements and fund capital expenditures for the next twelve months. The Post-RH Divestiture Plan is expected to be substantially complete by the end of 2025, though it may be expanded through 2026 following an assessment by the new Chief Executive Officer. The remaining limited support services from the RH Divestiture will terminate no later than three years following the October 2, 2023 closing.

Management Comments

• Committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery.
• Operating cash flow is expected to be sufficient to meet working capital requirements and fund capital expenditures in the next twelve months.
• With borrowing capacity, the company expects to have the ability to fund capital expenditures and other investments necessary to grow the business for the foreseeable future for both domestic and international operations.
• The Post-RH Divestiture Plan may be expanded following an assessment of the organization by the recent appointment of the Chief Executive Officer.

Industry Context

Avanos Medical operates in the medical technology sector, focusing on specialized nutrition and pain management solutions. The divestiture of the HA product line and the previous RH business aligns with a broader industry trend of companies streamlining portfolios to focus on core, higher-growth, or more profitable segments. The growth in Radiofrequency Ablation (RFA) solutions reflects increasing demand for minimally invasive pain relief therapies, a key area of innovation in the medical device industry. The challenges from tariffs and supply chain issues are common across global manufacturing and distribution sectors, particularly for companies with international supply chains and manufacturing bases like Mexico.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Subject to various legal proceedings, claims, and governmental inspections, audits, or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, and employment.
• The Deferred Prosecution Agreement (DPA) with the United States Department of Justice (DOJ) related to MicroCool surgical gowns expired on July 7, 2024, and the DOJ's case against the company was dismissed in January 2025.
• Operates in an industry characterized by extensive patent litigation, where competitors may claim products infringe upon their intellectual property, potentially leading to significant damage awards or injunctions.
• The ultimate resolution of any pending legal proceeding is not expected to have a material adverse effect on business, financial condition, results of operations, or liquidity.

Related Party Transactions

• Under the terms of the distribution agreement with Kimberly-Clark Corporation prior to the 2014 spin-off, the company is responsible for and obligated to indemnify Kimberly-Clark for legal proceedings, claims, and other liabilities primarily related to its business. No costs were incurred for such indemnification matters for the six months ended June 30, 2025 and 2024.

Stakeholder Impact

• Shareholders: The significant net loss and goodwill impairment will negatively impact shareholder equity and earnings per share. Modest revenue growth in core segments and strategic divestitures aim for long-term value.
• Employees: Ongoing restructuring initiatives (Transformation Process and Post-RH Divestiture Plan) involve employee severance and benefits costs, indicating potential workforce adjustments.
• Customers: Continued strong demand for Specialty Nutrition Systems products and growth in Radiofrequency Ablation solutions indicate positive customer reception in these areas. A decline in surgical pain and recovery sales suggests potential shifts in customer preference or market share.
• Suppliers: Reliance on foreign suppliers, particularly in China and Mexico, exposes the company to risks from tariffs and supply chain disruptions, which could impact supplier relationships and costs.
• Creditors: Compliance with debt covenants as of June 30, 2025, and sufficient operating cash flow for the next twelve months indicate stable creditworthiness, despite the net loss.

Next Steps

• Assess the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Potential expansion of the Post-RH Divestiture Plan initiatives through 2026, following an assessment by the new Chief Executive Officer.
• Remaining limited support services from the RH Divestiture will terminate no later than three years following the October 2, 2023 closing.
• Continued focus on meeting working capital requirements and funding capital expenditures from operating cash flow.

Key Dates

Recommendation

The significant goodwill impairment charge of $77.0 million, leading to a substantial net loss, is a major negative that cannot be overlooked. While the company shows modest revenue growth in its core Specialty Nutrition Systems segment and strong growth in Radiofrequency Ablation, the decline in surgical pain and recovery sales and the overall profitability hit are concerning. The ongoing restructuring and strategic divestitures (like the recent HA asset sale) indicate a clear effort to streamline and focus the business, which is a positive long-term strategy. However, the immediate financial performance is weak. Given the strategic repositioning and the one-time nature of the impairment, a 'hold' recommendation is appropriate. Investors should monitor the execution of the restructuring plan, the performance of the core segments, and the impact of the new CEO's assessment on future initiatives before considering further investment or divestment.

Keywords

Medical Devices, Healthcare, Specialty Nutrition, Pain Management, Radiofrequency Ablation, Enteral Feeding, Neonate Solutions, Surgical Pain Pumps, SEC Filing, 10-Q, Financial Results, Goodwill Impairment, Restructuring, Divestiture, Medical Technology